Role of circulating miR-182 and miR-150 as biomarkers for cirrhosis and hepatocellular carcinoma post HCV infection in Egyptian patients

•miR-182, significantly increased in non-cirrhotic HCV patients and may be used as circulatory biomarker in HCV infection.•miR-182 and miR-150 can detect fibrosis progression and cirrhosis in HCV patients.•miR-182 and miR-150 can detect malignant transformation in HCV patients and may be used as non...

Full description

Saved in:

Bibliographic Details
Published in:	Virus research Vol. 255; pp. 77 - 84
Main Authors:	Shaheen, Noha Mohamed Hosni, Zayed, Naglaa, Riad, Nermine Magdi, Tamim, Hend H., Shahin, Rasha Mohamed Hosny, Labib, Dalia A., ELsheikh, Suzan Mahrous, Moneim, Reham Abdel, Yosry, Ayman, khalifa, Rania H
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier B.V 15-08-2018
Subjects:	Adult Aged alpha-Fetoproteins - analysis Biomarkers, Tumor - blood Biomarkers, Tumor - genetics Carcinoma, Hepatocellular - blood Carcinoma, Hepatocellular - complications Carcinoma, Hepatocellular - epidemiology Carcinoma, Hepatocellular - genetics Disease Progression Egypt - epidemiology Female Gene Expression Regulation, Neoplastic Hepatitis C Hepatitis C, Chronic - blood Hepatitis C, Chronic - complications Hepatitis C, Chronic - epidemiology Hepatitis C, Chronic - genetics Hepatocellular carcinoma Humans Liver Cirrhosis - blood Liver Cirrhosis - complications Liver Cirrhosis - epidemiology Liver Cirrhosis - genetics Liver Neoplasms - blood Liver Neoplasms - complications Liver Neoplasms - epidemiology Liver Neoplasms - genetics Male MicroRNAs - blood MicroRNAs - genetics Middle Aged miR-150 miR-182 Prevalence qRT-PCR ROC Curve Sensitivity and Specificity Egypt miR-182 Hepatocellular carcinoma miR-150 Hepatitis C qRT-PCR
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	•miR-182, significantly increased in non-cirrhotic HCV patients and may be used as circulatory biomarker in HCV infection.•miR-182 and miR-150 can detect fibrosis progression and cirrhosis in HCV patients.•miR-182 and miR-150 can detect malignant transformation in HCV patients and may be used as noninvasive biomarkers.•Combining AFP with miR-182 and miR-150, improved sensitivity to (90%) and diagnostic accuracy to (80%) in HCC diagnosis. In Egypt, liver diseases are exceptionally high, maintaining the highest prevalence of hepatitis C virus (HCV) worldwide, and increasing rates of hepatocellular carcinoma (HCC). Available diagnostic methods show poor performance in early diagnosis of HCC. Definite pathogenic factors contributing in the development of HCV are still lacking. MicroRNAs have been reported as promising biomarkers for cancers diagnosis and in virus-host interaction. This study was conducted to detect the role of miR-182 and miR-150 as biomarkers for development of cirrhosis and malignant transformation in HCV infected patients. The expression of miR-182 and miR-150 was evaluated using real-time quantitative PCR (qRT-PCR) in 120 subjects: 40 HCC patients, 40 hepatitis C patients (20 cirrhotic and 20 non-cirrhotic HCV genotype 4) and 40 healthy controls. In HCC, statistically significant decrease of miR-182 and miR-150 compared to non-cirrhotic HCV patients (p = 0.015, p = 0.006 respectively) and of miR-150 compared to controls (p = 0.039). In cirrhotic HCV patients, significant down regulation of miR-182 and miR-150 compared to non-cirrhotic HCV (p = 0.003, p = 0.024 respectively). On the other hand, significant upregulation of miR-182 was observed in non-cirrhotic HCV compared to controls (p = 0.036). Alpha-fetoprotein (AFP) showed sensitivity 15% for HCC diagnosis at the cut-off value of 400 ng/ml, while combining AFP with miR-182 and miR-150, resulted in improving sensitivity to (90%) and diagnostic accuracy to (80%). miR-182 and miR-150 can be used as non invasive biomarkers for HCC and combination of these miRNAs and AFP markedly improve the diagnosis of HCC. Both miR-182 and miR-150 can also be used as predictive markers for detection of cirrhosis progression in HCV infected patients.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0168-1702 1872-7492
DOI:	10.1016/j.virusres.2018.07.004